Found 8 articles for: "FDA"
Hydroquinone and Emerging Depigmenting Agents: Clinical Guidelines, Regulatory History, and Global Safety Considerations
April 2026 | Volume 25 | Issue 4 | Original Article | 363 | Copyright © April 2026
Hydroquinone has long served as the gold standard for hyperpigmentation treatment, but safety concerns, regulatory changes, and growing interest in non-hydroquinone therapies have prompted reeval...
Read MoreRapid Clearance of Lichen Planus With Topical Tapinarof
April 2026 | Volume 25 | Issue 4 | Case Reports | 381 | Copyright © April 2026
Background: Lichen planus (LP) is an auto-inflammatory idiopathic condition affecting skin, mucous membranes, hair follicles, and nails that presents as pruritic, violaceous papu...
Read MoreBaricitinib-Related Adverse Events in Alopecia Areata and Rheumatoid Arthritis: A Comparative Study
March 2026 | Volume 25 | Issue 3 | Features | 286 | Copyright © March 2026
Regulatory Landscape of Regenerative Dermatology: Current Frameworks and Future
January 2026 | Volume 25 | Issue 1 | Original Article | 17 | Copyright © January 2026
Background: Regenerative dermatology is an emerging subspecialty that seeks to restore the structure and function of healthy skin. The United States lacks comprehensive regulator...
Read MoreFDA Boxed Warnings: Should Package Inserts Include Levels of Evidence?
December 2025 | Volume 24 | Issue 12 | Features | e67 | Copyright © December 2025
Many medications commonly used in dermatology come with package inserts that contain boxed warnings that are frequently not evidence-based. Boxed warnings are the most serious warnings that the U...
Read MoreThe Impact on Acne Treatment Regimens if Benzoyl Peroxide-Containing Products are Removed From the Market
June 2025 | Volume 24 | Issue 6 | Features | 586 | Copyright © June 2025
Benzyl peroxide (BPO) has been an important component of many acne treatment regimens. However, an independent testing laboratory, Valisure, filed a Citizen’s Petition with the US Food and ...
Read MoreNeed for Speed: Topical Roflumilast for Rapid Control of Seborrheic Dermatitis Flares
June 2025 | Volume 24 | Issue 6 | Case Reports | 634 | Copyright © June 2025
Seborrheic dermatitis is a common chronic inflammatory skin condition historically treated with topical antifungals and anti-inflammatory agents. While topical corticosteroids are frequently used...
Read MoreDisparities in Alopecia Areata and Vitiligo FDA-Approved Therapies in Medicaid Formularies
March 2025 | Volume 24 | Issue 3 | Editorials | e17 | Copyright © March 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
